University College London

Health Research, Inc.

Other

Midatech Limited

Middlesex University Higher Education Corporation

Ivan Maurice Roitt

Yasmin M Thanavala

Michael W Pride

Arvind Thakur

Thomas William Rademacher

Peter John Delves

Richard Harold Bayford

Andreas Demosthenous

Raymond Kruse Iles

Torben Lund

Keith G Huggins

Tom Rademacher

The use of nanoparticles for imaging a tumor in a mammal using electrical impedance tomography. The nanoparticles comprise a core of metal and/or semiconductor atoms to which are linked ligands that comprise a molecule capable of attaching to a specific tumor biomarker.

Detection of cancer with electrical impedance tomography

The present invention relates to modified human chorionic gonadotropin (&bgr;-hCG) proteins and their medical use as immunological contragestatives. The modification causes a reduction in the cross-reactivity of the modified &bgr;-hCG protein with luteinizing hormone (LH) as defined by the ability of both proteins to react with the same antibody.

Modified human chorionic gonadotropin (&bgr;-hCG) proteins and their medical use

The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permitted variants thereof, which, like 2F10, have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10. The shorter peptide chain comprising the amino acid residues Gly Tyr His Gly Ser Ser Leu Tyr and permitted variants thereof, also have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen.

Method of raising an immune response with an anti-idiotypic antibody

The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permited variants thereof, which, like 2F10, have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10. The shorter peptide chain comprising the amino acid residues Gly Tyr His Gly Ser Ser Leu Tyr and permited variants thereof, also have antigenic properties similar to the group specific 'a' determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen.

Peptide having antigenic properties similar to 'a 'determinant of

The standardization of a labelled constituent, such as anti-IgE, for use in a specific binding assay method is disclosed. The method involves standardizing a labelled ligand (eg., radiolabelled IgE) against a ligand reference substance (eg., WHO standard IgE) to determine the weight of IgE protein represented by the labelled ligand, expressed in terms of the reference substance (eg., WHO units). Anti-light chain antibodies are attached to a solid phase and contacted with varying concentrations of the labelled ligand to bind the ligand to the anti-light chain antibodies. The ligand is then contacted with the labelled constituent and the amount of labelled constituent, in relation to the amount of ligand protein present, expressed in terms of the reference substance, is determined. The labelled constituent is thus standardized, since the actual weight of a ligand can be determined from the amount of labelled constituent bound thereto. Also disclosed is an improved specific binding assay test method for determining the potency of an allergen extract. The test method generally involves inhibition by the soluble extract, of the binding of a ligand (provided by serum from an allergic individual) to solid-phase allergen as assessed by the standardized labelled constituent (anti-IgE). The improvement involves using a parallel model system of a second complex which consists of anti-light chain antibodies, labelled ligand and the standardized labelled constituent. Because the actual weight of a ligand bound to the labelled constituent is known, from the standardization procedure described above, the amount of standardized labelled constituent bound to the ligand in the first complex can be determined. The weight of ligand inhibited by addition of soluble allergen is then used as a measure of the potency of the allergen extract.

Specific binding assay techniques

Growing community of inventors

London, United Kingdom

Ivan Maurice Roitt